| Abstrakt: |
Objective: Our aim is to reveal the correlation between the molecular subtypes of breast cancer (BC) and contrast-enhanced breast magnetic resonance imaging (MRI) findings and to determine the possible molecular subtype and prognosis of the breast mass before the operation according to the MRI findings. In this way, it is aimed to ensure that contrast-enhanced breast MRI guides diagnosis and treatment. Methods: This study was conducted retrospectively between June 2015 and October 2020 including 265 patients who underwent dynamic contrast-enhanced breast MRI in our hospital and whose pathology results were consistent with invasive breast carcinoma. As a result of histopathological studies, patients were divided into molecular subtypes according to hormone receptor status (estrogen, progesterone, human epidermal growth factor receptor-2), and Ki-67 level, and MRI findings were evaluated for these subtypes according to the "Breast Imaging Reporting and Data System" updated in 2014 by the American College of Radiology. Results: A total of 265 cases of invasive BC were included. In these cases, the most common subtype was luminal A in 93 cases (35%), 79 luminal B tumor cases (29.8%), 51 triple-negative tumors (19.3%), and 42 HER2 tumor cases (6.7%). There was a statistically significant difference between molecular subtypes in terms of MRI findings and lesion presentation (p<0.0001). In addition, statistical analyses showed that there was a significant difference between the subgroups of mass shape and contour. In our study, no significant difference was found between the contrast enhancement pattern and contrast enhancement kinetic curves between molecular subtypes. Conclusion: There is a correlation between molecular subtypes and some MRI findings, and molecular subtypes can be determined early before the operation and prognostic markers can be revealed earlier. [ABSTRACT FROM AUTHOR] |
